Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 8/2016

01-08-2016 | Systematic Review

Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension

Authors: Shuyan Gu, Huimei Hu, Hengjin Dong

Published in: PharmacoEconomics | Issue 8/2016

Login to get access

Abstract

Background

The increasing survival of patients with pulmonary arterial hypertension (PAH) has shifted attention towards the disease burden that PAH imposes on patients and healthcare systems. Most studies emphasize epidemiology and medications, while large observational studies reporting on the health-related quality of life (HRQOL) of patients with PAH are lacking.

Objective

Our objective was to study the HRQOL of patients with PAH and to summarize the factors that influence it.

Methods

We conducted systematic literature searches in English (PubMed, Web of Knowledge, ScienceDirect and OVID) and Chinese (China National Knowledge Infrastructure, Wanfang Data, Chongqing VIP and SinoMed) databases to identify studies published from 2000 to 2015 assessing the HRQOL of patients with PAH. Search results were independently reviewed and extracted by two reviewers.

Results

Of 3392 records identified in the initial search, 20 eligible papers (19 English, 1 Chinese) were finally included. Studies used a range of instruments; the generic 36-item Short Form Survey (SF-36) was the most widely used, and the disease-specific Cambridge Pulmonary Hypertension Outcome Survey (CAMPHOR) was the second mostly widely used. Mean HRQOL scores assessed via the SF-36 (physical component summary [PCS] 25.4–80.1; mental component summary [MCS] 33.2–76.0) and CAMPHOR (symptom scores 3.1–17; total HRQOL 2.8–12.6; activity scores 3.8–18.1) varied across studies, reporting decreased HRQOL in patients. Mental health (depression, anxiety, stress), physical health (exercise capacity, symptoms) and medical therapies were reported to affect HRQOL.

Conclusion

We found that PAH places a substantial burden on patients, particularly in terms of HRQOL; however, the paucity of large observational studies in this area requires the attention of researchers, especially in China.
Appendix
Available only for authorised users
Literature
1.
Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425–36.CrossRefPubMed
2.
3.
4.
Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007;131:1917–28.CrossRefPubMed
5.
Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54:S43–54.CrossRefPubMed
6.
McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53:1573–619.CrossRefPubMed
7.
Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43:5S–12S.CrossRefPubMed
8.
9.
Jing ZC, Xu XQ, Han ZY, Wu Y, Deng KW, Wang H, et al. Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest. 2007;132:373–9.CrossRefPubMed
10.
Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137:376–87.CrossRefPubMed
11.
McDonough A, Matura LA, Carroll DL. Symptom experience of pulmonary arterial hypertension patients. Clin Nurs Res. 2011;20:120–34.CrossRefPubMed
12.
Flattery MP, Pinson JM, Savage L, Salyer J. Living with pulmonary artery hypertension: patients’ experiences. Heart Lung. 2005;34:99–107.CrossRefPubMed
13.
Delcroix M, Howard L. Pulmonary arterial hypertension: the burden of disease and impact on quality of life. Eur Respir Rev. 2015;24:621–9.CrossRefPubMed
14.
Buys R, Avila A, Cornelissen VA. Exercise training improves physical fitness in patients with pulmonary arterial hypertension: a systematic review and meta-analysis of controlled trials. BMC Pulm Med. 2015;15:40.CrossRefPubMedPubMedCentral
15.
Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173:1023–30.CrossRefPubMed
16.
Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007;30:104–9.CrossRefPubMed
17.
Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982–2006. Eur Respir J. 2007;30:1103–10.CrossRefPubMed
18.
Mikhail GW, Prasad SK, Li W, Rogers P, Chester AH, Bayne S, et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur Heart J. 2004;25:431–6.CrossRefPubMed
19.
Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148–57.CrossRefPubMed
20.
Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol. 2006;47:2049–56.CrossRefPubMed
21.
Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012;142:448–56.CrossRefPubMed
22.
McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galie N, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005;25:244–9.CrossRefPubMed
23.
Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46:529–35.CrossRefPubMed
24.
Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009;30:394–403.CrossRefPubMedPubMedCentral
25.
Cha KS, Cho KI, Seo JS, Choi JH, Park YH, Yang DH, et al. Effects of inhaled iloprost on exercise capacity, quality of life, and cardiac function in patients with pulmonary arterial hypertension secondary to congenital heart disease (the Eisenmenger syndrome) (from the EIGER Study). Am J Cardiol. 2013;112:1834–9.CrossRefPubMed
26.
Duffels M, Vis JC, van Loon R, Nieuwkerk PT, van Dijk A, Hoendermis ES, et al. Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down’s syndrome. Am J Cardiol. 2009;103:1309–15.CrossRefPubMed
27.
Vis JC, Duffels MG, Mulder P, de Bruin-Bon RH, Bouma BJ, Berger RM, et al. Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease. Int J Cardiol. 2013;164:64–9.CrossRefPubMed
28.
Chen YF, Jowett S, Barton P, Malottki K, Hyde C, Gibbs JS, et al. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health Technol Assess. 2009;13:1–320.CrossRefPubMed
29.
Mazzanti G, Albini A, Palazzini M, Monti E, Bachetti C, Rinaldi A, et al. A randomized open label study comparing first-line treatment with bosentan or sildenafil in Pulmonary Arterial Hypertension (PAH). Eur Heart J. 2013;341:186–7.
30.
Crackett RM, Hall A, Day MB, Desoyza JR, Small T, Fisher AJ, et al. Treatment outcomes in pulmonary arterial hypertension (PHA) associated with systemic sclerosis (Sscl.) in matched groups using either bosentan or sildenafil monotherapy. J Heart Lung Transpl. 2013;32S:S301.CrossRef
31.
Matura LA, Carroll DL. Human responses to pulmonary arterial hypertension: review of the literature. J Cardiovasc Nurs. 2010;25:420–7.CrossRefPubMed
32.
Chen H, Taichman DB, Doyle RL. Health-related quality of life and patient-reported outcomes in pulmonary arterial hypertension. Proc Am Thoracic Soc. 2008;5:623–30.CrossRef
33.
Rival G, Lacasse Y, Martin S, Bonnet S, Provencher S. Effect of pulmonary arterial hypertension-specific therapies on health-related quality of life: a systematic review. Chest. 2014;146:686–708.CrossRefPubMed
34.
Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015;8:2–10.CrossRefPubMed
35.
Zeng X, Liu H, Chen X, Leng W. Meta-analysis series 4: the methodological quality assessment tools for observational study. Chinese J Evid Based Cardiovasc Med. 2012;04:297–9.
36.
Cao S. The application of meta-analysis of observational studies in social factors and health—illustrated by the case of smoking. Hubei: Huazhong University Of Science And Technology; 2014.
37.
Rostom A, Dubé C, Cranney A, Saloojee N, Sy R, Mack D, et al. Celiac disease. Rockville (MD): US Agency for Healthcare Research and Quality; 2004 Sep. (Evidence Reports/Technology Assessments, No. 104.) Appendix D. Quality Assessment Forms [online]. http://​www.​ncbi.​nlm.​nih.​gov/​books/​NBK35156/​. Accessed 14 Dec 2015.
38.
39.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.CrossRefPubMed
40.
Shafazand S, Goldstein MK, Doyle RL, Hlatky MA, Gould MK. Health-related quality of life in patients with pulmonary arterial hypertension. Chest. 2004;126:1452–9.CrossRefPubMed
41.
Taichman DB, Shin J, Hud L, Archer-Chicko C, Kaplan S, Sager JS, et al. Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res. 2005;6.
42.
White J, Hopkins RO, Glissmeyer EW, Kitterman N, Elliott CG. Cognitive, emotional, and quality of life outcomes in patients with pulmonary arterial hypertension. Respir Res. 2006;7:55.CrossRefPubMedPubMedCentral
43.
Zlupko M, Harhay MO, Gallop R, Shin J, Archer-Chicko C, Patel R, et al. Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertension. Respir Med. 2008;102:1431–8.CrossRefPubMed
44.
Chen H, De Marco T, Kobashigawa EA, Katz PP, Chang VW, Blanc PD. Comparison of cardiac and pulmonary-specific quality-of-life measures in pulmonary arterial hypertension. Eur Respir J. 2011;38:608–16.CrossRefPubMedPubMedCentral
45.
Matura LA, McDonough A, Carroll DL. Cluster analysis of symptoms in pulmonary arterial hypertension: a pilot study. Eur J Cardiovasc Nurs. 2012;11:51–61.CrossRefPubMed
46.
Matura LA, McDonough A, Carroll DL. Predictors of health-related quality of life in patients with idiopathic pulmonary arterial hypertension. J Hosp Palliat Nurs. 2012;14:283–92.CrossRef
47.
Swetz KM, Shanafelt TD, Drozdowicz LB, Sloan JA, Novotny PJ, Durst LA, et al. Symptom burden, quality of life, and attitudes toward palliative care in patients with pulmonary arterial hypertension: results from a cross-sectional patient survey. J Heart Lung Transpl. 2012;31:1102–8.CrossRef
48.
Matura LA, McDonough A, Carroll DL. Health-related quality of life and psychological states in patients with pulmonary arterial hypertension. J Cardiovasc Nurs. 2014;29:178–84.CrossRefPubMed
49.
Matura LA, McDonough A, Hanlon AL, Carroll DL, Riegel B. Sleep disturbance, symptoms, psychological distress, and health-related quality of life in pulmonary arterial hypertension. Eur J Cardiovasc Nurs. 2015;14:423–30.CrossRefPubMed
50.
Talwar A, Sahni S, Kim EJ, Verma S, Kohn N. Dyspnea, depression and health related quality of life in pulmonary arterial hypertension patients. J Exerc Rehabil. 2015;11:259–65.CrossRefPubMedPubMedCentral
51.
Matura LA, McDonough A, Carroll DL. Symptom interference severity and health-related quality of life in pulmonary arterial hypertension. J Pain Symptom Manage. 2016;51:25–32.CrossRefPubMed
52.
Wilkens H, Grimminger F, Hoeper M, Stahler G, Ehlken B, Plesnila-Frank C, et al. Burden of pulmonary arterial hypertension in Germany. Respir Med. 2010;104:902–10.CrossRefPubMed
53.
Roman A, Barbera JA, Castillo MJ, Munoz R, Escribano P. Health-related quality of life in a national cohort of patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. Arch Bronconeumol. 2013;49:181–8.CrossRefPubMed
54.
McCabe C, Bennett M, Doughty N, Ross RM, Sharples L, Pepke-Zaba J. Patient-reported outcomes assessed by the CAMPHOR questionnaire predict clinical deterioration in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Chest. 2013;144:522–30.CrossRefPubMedPubMedCentral
55.
Vanhoof JMM, Delcroix M, Vandevelde E, Denhaerynck K, Wuyts W, Belge C, et al. Emotional symptoms and quality of life in patients with pulmonary arterial hypertension. J Heart Lung Transpl. 2014;33:800–8.CrossRef
56.
Cui M, Lin M, Zhang Q. The correlation between health behavior and quality of life in patients with pulmonary arterial hypertension. Chin J Prevent Control Chronic Dis. 2014;22:202–4.
57.
Small M, Piercy J, Pike J, Cerulli A. Incremental burden of disease in patients diagnosed with pulmonary arterial hypertension receiving monotherapy and combination vasodilator therapy. Adv Ther. 2014;31:168–79.CrossRefPubMed
58.
Yorke J, Armstrong I. The assessment of breathlessness in pulmonary arterial hypertension: reliability and validity of the Dyspnoea-12. Eur J Cardiovasc Nurs. 2014;13:506–14.CrossRefPubMed
59.
Blok IM, van Riel A, Schuuring MJ, Duffels MG, Vis JC, van Dijk A, et al. Decrease in quality of life predicts mortality in adult patients with pulmonary arterial hypertension due to congenital heart disease. Neth Heart J. 2015;23:278–84.CrossRefPubMedPubMedCentral
60.
Allen LA, Stevenson LW, Grady KL, Goldstein NE, Matlock DD, Arnold RM, et al. Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation. 2012;125:1928–52.CrossRefPubMedPubMedCentral
61.
Tartavoulle T. A predictive model of the effects of depression, anxiety, stress, six minute walk distance, and social support on health related quality of life in an adult pulmonary hypertension population. Clin Nurse Spec. 2014;28:E40.CrossRef
62.
Batal O, Khatib OF, Bair N, Aboussouan LS, Minai OA. Sleep quality, depression, and quality of life in patients with pulmonary hypertension. Lung. 2011;189:141–9.CrossRefPubMed
63.
Ulrich S, Fischler M, Speich R, Bloch KE. Sleep-related breathing disorders in patients with pulmonary hypertension. Chest. 2008;133:1375–80.CrossRefPubMed
64.
McCollister DH, Beutz M, McLaughlin V, Rumsfeld J, Masoudi FA, Tripputi M, et al. Depressive symptoms in pulmonary arterial hypertension: prevalence and association with functional status. Psychosomatics. 2010;51:339.CrossRefPubMed
65.
Lowe B, Grafe K, Ufer C, Kroenke K, Grunig E, Herzog W, et al. Anxiety and depression in patients with pulmonary hypertension. Psychosom Med. 2004;66:831–6.CrossRefPubMed
66.
67.
Harzheim D, Klose H, Pinado FP, Ehlken N, Nagel C, Fischer C, et al. Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Respir Res. 2013;14:104.CrossRefPubMedPubMedCentral
68.
Kim EJ, Verma S, Sahni S, Athaanasiou K, Patel P, Kohn N, et al. Dyspnea, depression, and health related quality of life [HRQOL] in patients with pulmonary artery hypertension [PAH]. Chest. 2013;144S.
69.
Halank M, Einsle F, Lehman S, Bremer H, Ewert R, Wilkens H, et al. Exercise capacity affects quality of life in patients with pulmonary hypertension. Lung. 2013;191:337–43.CrossRefPubMed
70.
Pepke-Zaba J, Beardsworth A, Chan M, Angalakuditi M. Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension. Curr Med Res Opin. 2009;25:2479–85.CrossRefPubMed
71.
Cicero C, Franchi SM, Barreto AC, Lopes AA. Lack of tight association between quality of life and exercise capacity in pulmonary arterial hypertension. Arq Bras Cardiol. 2012;99:876–85.CrossRefPubMed
72.
Keogh AM, McNeil KD, Wlodarczyk J, Gabbay E, Williams TJ. Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J Heart Lung Transpl. 2007;26:181–7.CrossRef
73.
Wang RC, Jiang FM, Zheng QL, Li CT, Peng XY, He CY, et al. Efficacy and safety of sildenafil treatment in pulmonary arterial hypertension: a systematic review. Respir Med. 2014;108:531–7.CrossRefPubMed
74.
Udeoji DU, Schwarz ER. Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension. Ther Adv Respir Dis. 2013;7:39–49.CrossRefPubMed
75.
Croxtall JD, Lyseng-Williamson KA. Tadalafil: in pulmonary arterial hypertension. Drugs. 2010;70:479–88.CrossRefPubMed
76.
Somaini SU, Vatandaslar S, Huber LC, Treder U, Breitenstein A, Speich R. Imatinib improves hemodynamics and quality of life in pulmonary arterial hypertension. Am J Resp Crit Care. 2011;183.
77.
Jacobs W, Vonk-Noordegraaf A. Epoprostenol in pulmonary arterial hypertension. Expert Opin Drug Metab Toxicol. 2009;5:83–90.CrossRefPubMed
78.
Ewert R, Glaser S, Bollmann T, Schaper C. Inhaled iloprost for therapy in pulmonary arterial hypertension. Expert Rev Respir Med. 2011;5:145–52.CrossRefPubMed
79.
Schuuring MJ, Vis JC, van Dijk AP, van Melle JP, Vliegen HW, Pieper PG, et al. Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial. Eur J Heart Fail. 2013;15:690–8.CrossRefPubMed
80.
McLaughlin VV. Medical management of primary pulmonary hypertension. Expert Opin Pharmacother. 2002;3:159–65.CrossRefPubMed
81.
Chen H, Rosenzweig EB, Gotzkowsky SK, Arneson C, Nelsen AC, Bourge RC. Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension. Health Qual Life Outcomes. 2013;11:31.CrossRefPubMedPubMedCentral
82.
Rubenfire M, Lippo G, Bodini BD, Blasi F, Allegra L, Bossone E. Evaluating health-related quality of life, work ability, and disability in pulmonary arterial hypertension: an unmet need. Chest. 2009;136:597–603.CrossRefPubMed
83.
Cenedese E, Speich R, Dorschner L, Ulrich S, Maggiorini M, Jenni R, et al. Measurement of quality of life in pulmonary hypertension and its significance. Eur Respir J. 2006;28:808–15.CrossRefPubMed
84.
Gomberg-Maitland M, Thenappan T, Rizvi K, Chandra S, Meads DM, McKenna SP. United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). J Heart Lung Transpl. 2008;27:124–30.CrossRef
85.
Coffin D, Duval K, Martel S, Granton J, Lefebvre MC, Meads DM, et al. Adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) into French-Canadian and English-Canadian. Can Respir J. 2008;15:77–83.CrossRefPubMedPubMedCentral
86.
Ganderton L, Jenkins S, McKenna SP, Gain K, Fowler R, Twiss J, et al. Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Australian and New Zealand population. Respirology. 2011;16:1235–40.CrossRefPubMed
87.
Yorke J, Corris P, Gaine S, Gibbs JS, Kiely DG, Harries C, et al. emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. Eur Respir J. 2014;43:1106–13.CrossRefPubMed
88.
Brundage M, Blazeby J, Revicki D, Bass B, de Vet H, Duffy H, et al. Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. Qual Life Res. 2013;22:1161–75.CrossRefPubMed
89.
Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T. Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population. Appl Health Econ Health Policy. 2011;9:293–303.CrossRefPubMed
90.
Krumholz HM. Patient-centered medicine: the next phase in health care. Circ Cardiovasc Qual Outcomes. 2011;4:374–5.CrossRefPubMed
91.
Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med. 1997;44:681–92.CrossRefPubMed
92.
Goodlin SJ, Hauptman PJ, Arnold R, Grady K, Hershberger RE, Kutner J, et al. Consensus statement: palliative and supportive care in advanced heart failure. J Card Fail. 2004;10:200–9.CrossRefPubMed
93.
Jaarsma T, Beattie JM, Ryder M, Rutten FH, McDonagh T, Mohacsi P, et al. Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2009;11:433–43.CrossRefPubMed
94.
Pantilat SZ, Steimle AE. Palliative care for patients with heart failure. JAMA. 2004;291:2476–82.CrossRefPubMed
95.
Rizzieri AG, Verheijde JL, Rady MY, McGregor JL. Ethical challenges with the left ventricular assist device as a destination therapy. Philos Ethics Humanit Med. 2008;3:20.CrossRefPubMedPubMedCentral
96.
Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46:903–75.CrossRefPubMed
97.
Arena R, Cahalin LP, Borghi-Silva A, Myers J. The effect of exercise training on the pulmonary arterial system in patients with pulmonary hypertension. Prog Cardiovasc Dis. 2015;57:480–8.CrossRefPubMed
Metadata
Title
Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension
Authors
Shuyan Gu
Huimei Hu
Hengjin Dong
Publication date
01-08-2016
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 8/2016
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-016-0395-y

Other articles of this Issue 8/2016

PharmacoEconomics 8/2016 Go to the issue

Current Opinion

Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges

Original Research Article

Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria

Review Article

Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal—An Evidence Review Group Perspective

Original Research Article

Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT Trial

Systematic Review

A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions

Original Research Article

The Impact of Different DCE-Based Approaches When Anchoring Utility Scores